AliveDx Celebrates New Milestone in Diagnostic Innovation
AliveDx has made a significant advancement in the field of diagnostics by receiving the esteemed IVDR-CE mark for its MosaiQ AiPlex CTDplus multiplex assay. This innovative assay is poised to support clinicians and laboratories in providing rapid and accurate diagnoses for Systemic Autoimmune Rheumatic Diseases (SARDs).
Understanding Systemic Autoimmune Rheumatic Diseases
Systemic autoimmune rheumatic diseases such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus, and Sjögren's syndrome impact millions globally. These conditions are marked by the body's immune system mistakenly attacking its tissues, leading to a myriad of symptoms that complicate diagnosis. With overlapping clinical manifestations, healthcare providers often face challenges in ensuring timely and precise diagnoses.
Challenges in Diagnosis
Diagnosing these complex diseases requires a multifaceted approach due to the overlapping nature of symptoms. The presence of multiple autoantibodies can exponentially increase the difficulty in accurately identifying a specific condition. Traditional testing methods often rely on a series of sequential tests, leading to delays in obtaining results.
The MosaiQ AiPlex CTDplus Assay: A Game Changer
The MosaiQ AiPlex CTDplus assay stands out with its syndromic testing capabilities. This advanced diagnostic tool utilizes a single step to analyze a mere 10 ?l of the patient’s sample, enabling healthcare providers to obtain comprehensive results swiftly. By detecting a broad array of autoantibodies, it provides a detailed insight into the patient's immunological status.
Features and Benefits of MosaiQ AiPlex CTDplus
The assay includes 15 essential autoantibody markers, aligning with the latest clinical guidelines. This provides clinicians with a wealth of information, facilitating more informed decision-making and improving patient care. The conversion to a singular testing process streamlines laboratory workflow, enhancing efficiency in high-demand environments.
Future Directions for AliveDx
Manuel O. Méndez, CEO of AliveDx, expressed enthusiasm regarding this achievement, highlighting its implications for patient care. The continuous development of advanced diagnostics is crucial for effectively managing conditions like RA and CTD. AliveDx is dedicated to expanding its offerings, with plans to introduce additional multiplex tests focusing on vasculitis and antiphospholipid syndrome.
The MosaiQ System: Innovation in Action
The MosaiQ platform represents state-of-the-art technology in the diagnostic landscape. It supports multiplexed testing, capable of processing up to 1,275 disease markers hourly, which caters to the increasing demand for efficiency in laboratories. Furthermore, incorporating RFID technology in microarray magazines enhances accuracy, reducing manual errors and improving turnaround times.
Committed to Advancing Patient Care
AliveDx's commitment to quality and precision reflects its mission to innovate and improve patient outcomes. With over 30 years of experience in in-vitro diagnostics, AliveDx aims to simplify laboratory processes while delivering reliable, fast results. Their portfolio includes brands like Alba and LumiQ, which contribute to a comprehensive suite of diagnostic solutions.
About AliveDx
AliveDx thrives on empowering healthcare providers with the tools they need to make accurate diagnoses. Their vision focuses on enhancing the lives of patients through innovative solutions that transform diagnostics. By simplifying workflows, AliveDx not only improves efficiency but also supports clinicians in making better, faster clinical decisions.
Frequently Asked Questions
What is the MosaiQ AiPlex CTDplus assay?
The MosaiQ AiPlex CTDplus assay is a multiplex testing solution for diagnosing Systemic Autoimmune Rheumatic Diseases, providing a comprehensive autoantibody profile for patients.
How does the MosaiQ system streamline laboratory workflows?
The system automates the testing process, allowing faster results from smaller sample sizes, which reduces manual errors and increases efficiency.
What are Systemic Autoimmune Rheumatic Diseases?
These are autoimmune conditions characterized by the immune system attacking its own tissues, with conditions including Rheumatoid Arthritis and Systemic Lupus Erythematosus.
What does IVDR-CE mark signify?
The IVDR-CE mark indicates that a medical device complies with European regulations for in-vitro diagnostics, ensuring safety and efficacy.
What is AliveDx’s mission?
AliveDx aims to empower diagnostic insights and innovate for life, enhancing patient care through advanced diagnostics and laboratory solutions.
